Research map: Case Report: Non-invasive [89Zr]Zr-DFO-trastuzumab positron emission tomography in the multimodal characterisation of platinum-resistant high-grade serous ovarian cancer

Back to the article

Papers in this map

  1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries · Hyuna Sung · 2021 · 114646 citations · Cited by this paper
  2. The effect of resizing on the natural appearance of scintigraphic images: an image similarity analysis · 2025 · Related
  3. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  4. Case Report: Utility of brain [18F]FDG PET/CT in the diagnosis of Sydenham's chorea · 2024 · Related
  5. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  6. Case Report: 18F-Fluorocholine PET/CT for detecting brown tumours in patients with hyperparathyroidism: a short case series and literature review · 2025 · Related
  7. Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer · Eli C. F. Dijkers · 2010 · 815 citations · Cited by this paper
  8. On the construction of a large-scale database of AI-assisted annotating lung ventilation-perfusion scintigraphy for pulmonary embolism (VQ4PEDB) · 2025 · Related
  9. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints · Michael A. Lisio · 2019 · 722 citations · Cited by this paper
  10. Validating image-derived input functions of dynamic 18F-FDG long axial field-of-view PET/CT studies · 2025 · Related
  11. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing · Josef Rüschoff · 2010 · 495 citations · Cited by this paper
  12. Radiolabeled para-I-nimesulide: an unexpected tracer for imaging peripheral inflammation · 2026 · Related
  13. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial · Géraldine Gebhart · 2015 · 359 citations · Cited by this paper
  14. Case Report: Role of MRI, CT, and 18F-FDG PET/CT in staging and response assessment of pediatric synovial sarcoma · 2026 · Related
  15. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT · Gary A. Ulaner · 2016 · 191 citations · Cited by this paper
  16. Bayesian modeling with locally adaptive prior parameters in small animal imaging · 2025 · Related
  17. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2–Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer · Gary A. Ulaner · 2017 · 141 citations · Cited by this paper
  18. Ionising radiation exposure-induced regulation of selected biomarkers and their impact in cancer and treatment · 2024 · Related
  19. Screening for ovarian cancer: imaging challenges and opportunities for improvement · Kelsey B. Mathieu · 2017 · 121 citations · Cited by this paper
  20. Trastuzumab deruxtecan in breast cancer · Miguel Martín · 2024 · 95 citations · Cited by this paper
  21. Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer · Farrokh Dehdashti · 2018 · 89 citations · Cited by this paper
  22. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial · Nadia Harbeck · 2025 · 83 citations · Cited by this paper
  23. Site-specifically labeled 89Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model · Lotte K. Kristensen · 2019 · 74 citations · Cited by this paper
  24. Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers · Eros Azzalini · 2023 · 53 citations · Cited by this paper
  25. Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial) · Magdalena Mileva · 2024 · 53 citations · Cited by this paper
  26. Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers · Sepideh Hatamikia · 2023 · 45 citations · Cited by this paper
  27. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes · Min-Hwan Sohn · 2021 · 28 citations · Cited by this paper
  28. Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89 Zr-Trastuzumab PET: A Pilot Study · Melissa Amy Lumish · 2022 · 25 citations · Cited by this paper
  29. Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance · Sara Polajžer · 2025 · 23 citations · Cited by this paper
  30. The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features · Angela Santoro · 2024 · 22 citations · Cited by this paper
  31. Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer · Paweł Kordowitzki · 2025 · 21 citations · Cited by this paper
  32. Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary · Courtney A. Penn · 2023 · 18 citations · Cited by this paper
  33. Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial · Mattia Rediti · 2024 · 11 citations · Cited by this paper
  34. Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis · Randy Yeh · 2025 · 11 citations · Cited by this paper
  35. Predicting incomplete cytoreduction in patients with advanced ovarian cancer · EVA KATHARINA EGGER · 2022 · 10 citations · Cited by this paper
  36. Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial · Nadia Harbeck · 2024 · 8 citations · Cited by this paper
  37. Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives · Ruiting Fu · 2025 · 8 citations · Cited by this paper
  38. HER2 Expression in Peritoneal Dissemination of High-Grade Serous Ovarian Carcinoma: A Comparative Study of Immunohistochemical Reactivity Using Four HER2 Antibodies · Min‐Kyung Yeo · 2022 · 4 citations · Cited by this paper
  39. 69O Novel regimens for persistent/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2/GOG-3051/BOUQUET phase II study results · Isabelle Laure Ray-Coquard · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)